Intentar ORO - Gratis
Overused antibiotics no longer work for 'sizeable' Indian population
Mint Mumbai
|January 12, 2024
Antibiotics routinely prescribed to treat common ailments no longer work as bacteria have developed resistance to these drugs due to their overuse in India, a government body said, echoing concerns long voiced by international experts.
In a report, the National Centre for Disease Control (NCDC) mentioned about third-generation cephalosporins, imidazoles, amino-glycosides, ceftriaxone, metronidazole, amikacin and piperacillin, which are used to treat cold, fever, skin diseases and urinary tract infection.
Companies that make these antibiotics in India include Alkem Laboratories Ltd, Mankind Pharma Ltd, Zuventus Healthcare Ltd, Cadila Pharmaceuticals Ltd, Surya Pharmaceutical Ltd, Aristo Pharmaceuticals Pvt. Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd and Pfizer India Ltd.
Esta historia es de la edición January 12, 2024 de Mint Mumbai.
Suscríbete a Magzter GOLD para acceder a miles de historias premium seleccionadas y a más de 9000 revistas y periódicos.
¿Ya eres suscriptor? Iniciar sesión
MÁS HISTORIAS DE Mint Mumbai
Mint Mumbai
No silver bullet
Is silver set to emerge from the shadow of gold as a precious metal? Although its price fell about 2% on Tuesday, it has been enjoying a bull run that makes this dip seem more like a pause for breath than the start of a correction.
1 min
December 03, 2025
Mint Mumbai
Profits, credit lift fundraising by corporates
Corporate fundraising activity saw a significant revival in the September 2025 quarter.
2 mins
December 03, 2025
Mint Mumbai
MAKING SENSE OF IMF RATING AND GDP DATA
India's Q2 growth surpassed expectations, but the IMF rated GDP data quality a 'C'. While India is addressing many of the issues, it's a reminder that the country cannot afford long gaps in statistical improvements.
4 mins
December 03, 2025
Mint Mumbai
Chinese rare-earth dealers are dodging Beijing’s export curbs
Chinese rare-earth magnet companies are finding workarounds to their government's onerous export restrictions, as they seek to keep sales flowing to Western buyers without falling afoul of Chinese authorities.
4 mins
December 03, 2025
Mint Mumbai
Lenskart tops Nykaa on margins
In Lenskart Solutions Ltd's first results post-listing, investor focus should be on the comparison of pro forma financials.
2 mins
December 03, 2025
Mint Mumbai
State-owned banks flag deposit rate woes on policy eve
State-owned lenders have alerted the banking regulator that their inability to cut deposit rates as fast as loan rates is taking a toll on interest margins, three people familiar with the development said.
3 mins
December 03, 2025
Mint Mumbai
India’s battery dreams trip on visa hurdles for Chinese pros
Problems in renewal of visas for Chinese technicians have slowed the pace of buildout of India’s lithium-ion battery manufacturing factories for electric vehicles and energy storage, according to two people aware of the matter.
2 mins
December 03, 2025
Mint Mumbai
All eyes on RBI as fresh fall brings rupee closer to 90
The Indian rupee came within kissing distance of 90 to a dollar on Tuesday before likely central bank intervention rescued it from the brink, but not before it touched a new all-time low.
3 mins
December 03, 2025
Mint Mumbai
Samsung debuts 1st trifold smartphone
Samsung Electronics Co. unveiled its first so-called trifold smartphone, flaunting its engineering prowess in foldable devices even as the broader category has yet to catch on with consumers.
2 mins
December 03, 2025
Mint Mumbai
Meesho under fire from investors over SBI Funds allotment
Meesho Ltd's anchor book faced a setback after several major investors pulled out when the Indian e-commerce firm was said to have allocated about a quarter of the shares in this tranche to SBI Funds Management Pvt,, the country’s largest asset manager, according to people familiar with the matter.
1 mins
December 03, 2025
Listen
Translate
Change font size

